Biogen shares drop after Morgan Stanley downgrade; rest of biotech also dragged lower
March 16, 2017 at 10:06 AM EDT
Biogen shares are fully valued following the spinoff of its hemophilia business, Morgan Stanley argues.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.